Detection of Borrelia burgdorferi nucleic acids after antibiotic treatment does not confirm viability
- PMID: 23269733
- PMCID: PMC3592055
- DOI: 10.1128/JCM.02785-12
Detection of Borrelia burgdorferi nucleic acids after antibiotic treatment does not confirm viability
Abstract
The persistence of dormant, noncultivable Borrelia burgdorferi after ceftriaxone treatment was examined. B. burgdorferi isolates were cultivated in Barbour-Stoenner-Kelly medium in the presence or absence of ceftriaxone, and cultures were monitored for up to 56 days. Viability of B. burgdorferi was assessed by subculture, growth, morphology, and pH (as a surrogate for metabolic activity). In addition, the presence of B. burgdorferi DNA and mRNA was assayed by PCR and by real-time reverse transcription (RT)-PCR, respectively. Spirochetes could not be successfully subcultured by day 3 after exposure to ceftriaxone. In cultures treated with ceftriaxone, the pH of the culture medium did not change through day 56, whereas it declined by at least 1 pH unit by 14 days in untreated cultures. These results suggest that B. burgdorferi viability is rapidly eliminated after antibiotic treatment. Nevertheless, DNA was detected by B. burgdorferi-specific PCR for up to 56 days in aliquots from both ceftriaxone-treated and untreated cultures. In addition, although ceftriaxone treatment resulted in a reduction in the quantities of transcript for ospC, ospA, flaB, and pfk, certain mRNAs could be detected through day 14. Transcript for all 4 genes was essentially undetectable after 28 days of treatment. Taken together, the results suggest that B. burgdorferi DNA and mRNA can be detected in samples long after spirochetes are no longer viable as assessed by classic microbiological parameters. PCR positivity in the absence of culture positivity following antibiotic treatment in animal and human studies should be interpreted with caution.
Figures

Similar articles
-
Persistence of borrelial DNA in the joints of Borrelia burgdorferi-infected mice after ceftriaxone treatment.APMIS. 2010 Sep 1;118(9):665-73. doi: 10.1111/j.1600-0463.2010.02615.x. APMIS. 2010. PMID: 20718718
-
Resurgence of persisting non-cultivable Borrelia burgdorferi following antibiotic treatment in mice.PLoS One. 2014 Jan 23;9(1):e86907. doi: 10.1371/journal.pone.0086907. eCollection 2014. PLoS One. 2014. PMID: 24466286 Free PMC article.
-
Decorin binding proteins of Borrelia burgdorferi promote arthritis development and joint specific post-treatment DNA persistence in mice.PLoS One. 2015 Mar 27;10(3):e0121512. doi: 10.1371/journal.pone.0121512. eCollection 2015. PLoS One. 2015. PMID: 25816291 Free PMC article.
-
Antibiotic treatment of animals infected with Borrelia burgdorferi.Clin Microbiol Rev. 2009 Jul;22(3):387-95. doi: 10.1128/CMR.00004-09. Clin Microbiol Rev. 2009. PMID: 19597005 Free PMC article. Review.
-
Direct detection methods for Lyme Borrelia, including the use of quantitative assays.Vector Borne Zoonotic Dis. 2002 Winter;2(4):223-31. doi: 10.1089/153036602321653806. Vector Borne Zoonotic Dis. 2002. PMID: 12804163 Review.
Cited by
-
Persistent Borrelia burgdorferi Sensu Lato Infection after Antibiotic Treatment: Systematic Overview and Appraisal of the Current Evidence from Experimental Animal Models.Clin Microbiol Rev. 2022 Dec 21;35(4):e0007422. doi: 10.1128/cmr.00074-22. Epub 2022 Oct 12. Clin Microbiol Rev. 2022. PMID: 36222707 Free PMC article. Review.
-
Persister Development by Borrelia burgdorferi Populations In Vitro.Antimicrob Agents Chemother. 2015 Oct;59(10):6288-95. doi: 10.1128/AAC.00883-15. Epub 2015 Jul 27. Antimicrob Agents Chemother. 2015. PMID: 26248368 Free PMC article.
-
Relevance of chronic lyme disease to family medicine as a complex multidimensional chronic disease construct: a systematic review.Int J Family Med. 2014;2014:138016. doi: 10.1155/2014/138016. Epub 2014 Nov 24. Int J Family Med. 2014. PMID: 25506429 Free PMC article. Review.
-
Borrelia burgdorferi induces a type I interferon response during early stages of disseminated infection in mice.BMC Microbiol. 2016 Mar 8;16:29. doi: 10.1186/s12866-016-0644-4. BMC Microbiol. 2016. PMID: 26957120 Free PMC article.
-
Generality of Post-Antimicrobial Treatment Persistence of Borrelia burgdorferi Strains N40 and B31 in Genetically Susceptible and Resistant Mouse Strains.Infect Immun. 2019 Sep 19;87(10):e00442-19. doi: 10.1128/IAI.00442-19. Print 2019 Oct. Infect Immun. 2019. PMID: 31308087 Free PMC article.
References
-
- Centers for Disease Control and Prevention 2012. Final 2011 reports of nationally notifiable diseases. MMWR Morb. Mortal. Wkly. Rep. 61:624–627
-
- Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, Krause PJ, Bakken JS, Strle F, Stanek G, Bockenstedt L, Fish D, Dumler JS, Nadelman RB. 2006. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin. Infect. Dis. 43:1089–1134 - PubMed
-
- Cerar D, Cerar T, Ruzic-Sabljic E, Wormser GP, Strle F. 2010. Subjective symptoms after treatment of early Lyme disease. Am. J. Med. 123:79–86 - PubMed
-
- Nowakowski J, Nadelman RB, Sell R, McKenna D, Cavaliere LF, Holmgren D, Gaidici A, Wormser GP. 2003. Long-term follow-up of patients with culture-confirmed Lyme disease. Am. J. Med. 115:91–96 - PubMed
-
- Fallon BA, Keilp JG, Corbera KM, Petkova E, Britton CB, Dwyer E, Slavov I, Cheng J, Dobkin J, Nelson DR, Sackeim HA. 2008. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 70:992–1003 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical